Aprocitentan and its relationship: understanding its clinical use

Aprocitentan and aprocitentan are the English and Chinese names of the same drug. They refer to the same drug, which is mainly used to treat refractory hypertension . Aprocitentan (Aprocitentan) is an endothelin A receptor antagonist, clinically used to reduce blood pressure in patients with hypertension that cannot be adequately controlled by conventional antihypertensive drugs. It has shown significant effects in the treatment of refractory hypertension and is particularly suitable for combined use in patients for whom other antihypertensive drugs are ineffective.

The mechanism of action of aprecitentan is mainly by blocking endothelinA receptors, reducing blood vessel contraction and promoting blood vessel dilation, thereby achieving the effect of lowering blood pressure. Endothelin is a potent vasoconstrictor that is often overactive in patients with hypertension. By inhibiting the effect of endothelin A, Aprecitentan can effectively relieve vascular tension and help patients stabilize blood pressure, thereby reducing the risk of cardiovascular events.

In clinical application, aprecitentan is often used as a second-line drug in combination with other antihypertensive drugs. It is particularly important in patients for whom single drug therapy is not effective, especially in patients with difficult to control hypertension. The drug not only effectively lowers blood pressure, but also significantly reduces the risk of cardiovascular events such as stroke and myocardial infarction. Therefore, it provides a new treatment option for patients with refractory hypertension and helps improve the quality of life of these patients.

It should be noted that aprecitentan is not the drug of choice when used alone and is often used in combination with other antihypertensive drugs. During the treatment process, the patient's blood pressure needs to be monitored regularly to ensure the treatment effect. At the same time, possible side effects, such as hypotension, liver function problems, etc., should also be paid attention to. In addition, patients with hepatic impairment need to be particularly careful when using aprecitentan, as the drug is metabolized in the liver and may increase liver burden.

Reference materials:https://go.drugbank.com/drugs/DB15059